Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | GAK | O14976 | 3/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.39 |
| ▸ | COQ8A | Q8NI60 | 2/20 | 0.39 |
| ▸ | NLK | Q9UBE8 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 3/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4582739 | 0.78 | MAPK9 (0.51) | SRCDYRK1AG6PDPLK1PTK2 | |
| SCHEMBL4783058 | 0.75 | SRC (0.44) | SRCDYRK1AGAKEGFRRIPK2 | |
| SCHEMBL4580624 | 0.74 | KDM4E (0.39) | ARALDH1A1 | |
| SCHEMBL4578991 | 0.72 | SRC (0.40) | SRCALDH1A1 | |
| SCHEMBL4582113 | 0.71 | TBK1 (0.42) | SRCDYRK1AGAKEGFRRIPK2 | |
| SCHEMBL4581255 | 0.71 | DYRK1A (0.41) | SRCDYRK1AGAKEGFRRIPK2 | |
| SCHEMBL4581125 | 0.71 | SRC (0.41) | SRCDYRK1AGAKEGFRRIPK2 | |
| SCHEMBL4581973 | 0.71 | DYRK1A (0.41) | SRCDYRK1AGAKEGFRRIPK2 | |
| SCHEMBL4580964 | 0.71 | TBK1 (0.51) | SRCGAKEGFRRIPK2COQ8A | |
| SCHEMBL4580429 | 0.67 | SRC (0.51) | SRCEGFRARALDH1A1ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | claimed |
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| WO-2008024963-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | RB1, MKI67, CCNB1 | SRC 1098/4885DYRK1A 2145/4885GAK 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.